Singapore okays pill for easier DVT treatment
A new anti-coagulant pill will simplify the treatment of deep vein thrombosis (DVT), bringing greater convenience and reduced costs for patients and hospitals.
The Bayer-developed Xarelto, or Rivaroxaban, which has been approved by the Health Sciences Authority here, is the first oral, single-drug approach for the treatment and prevention of DVT.
The condition occurs when a blood clot forms in veins deep inside the muscles of the legs. If the clot travels to the lungs, it can block blood supply, in a potentially fatal problem known as a pulmonary embolism.
Treatment for DVT currently involves daily injections of an anti-coagulant and oral medication. Frequent blood tests are also needed to check for possible food and drug interactions.